Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36652917.
- Also identified by DOI 10.1016/j.xcrm.2022.100908 and PMC identifier 9873932.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In a recent issue of Cancer Cell, Amodio and colleagues report an interesting method of modulating immunosurveillance in colorectal tumors with DNA mismatch repair (MMR) heterogeneity.<sup>1</sup> By pharmacologically enriching the MMR deficient (MMRd) component using 6-thioguanine, they demonstrate improved tumor control in murine models.
Medical subject headings
- DNA Mismatch Repair
- Colorectal Neoplasms